{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/inflation-reduction-act-ira-assessing-implications-medicare-drug-price-negotiations-drug#webpage",
"url": "https://www.fortrea.com/insights/inflation-reduction-act-ira-assessing-implications-medicare-drug-price-negotiations-drug",
"name": "Inflation Reduction Act (IRA): Assessing the implications of Medicare drug price negotiations for drug development sponsors",
"description": "Explore this Fortrea white paper examining how the Inflation Reduction Act is reshaping pharmaceutical pricing, reimbursement strategy, market access, and clinical development planning across the life sciences industry. The white paper highlights the impact of Medicare drug pricing reforms, evolving reimbursement pressures, commercialization challenges, and policy-driven market dynamics on pharmaceutical development and portfolio strategy. Learn how life sciences organizations can adapt clinical development plans, optimize lifecycle management, strengthen evidence generation strategies, and navigate changing healthcare policy expectations to support long-term commercial success, regulatory readiness, and sustainable market positioning in an evolving pharmaceutical landscape."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Inflation Reduction Act (IRA): Assessing the implications of Medicare drug price negotiations for drug development sponsors",
"item": "https://www.fortrea.com/insights/inflation-reduction-act-ira-assessing-implications-medicare-drug-price-negotiations-drug"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/inflation-reduction-act-ira-assessing-implications-medicare-drug-price-negotiations-drug#whitepaper",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/inflation-reduction-act-ira-assessing-implications-medicare-drug-price-negotiations-drug#webpage"
},
"headline": "Inflation Reduction Act Impact on Pharmaceutical Pricing & Market Access Strategy | Fortrea White Paper",
"description": "Explore this Fortrea white paper examining how the Inflation Reduction Act is reshaping pharmaceutical pricing, reimbursement strategy, market access, and clinical development planning across the life sciences industry. The white paper highlights the impact of Medicare drug pricing reforms, evolving reimbursement pressures, commercialization challenges, and policy-driven market dynamics on pharmaceutical development and portfolio strategy. Learn how life sciences organizations can adapt clinical development plans, optimize lifecycle management, strengthen evidence generation strategies, and navigate changing healthcare policy expectations to support long-term commercial success, regulatory readiness, and sustainable market positioning in an evolving pharmaceutical landscape.",
"genre": "White Paper",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2024-11-15",
"dateModified": "2024-11-15",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2024-11/WP_0063_Inflation%20Reduction_0924_HiRes.pdf",
"encodingFormat": "application/pdf"
}
}
]
}